FY2026 EPS Estimates for Exelixis Lifted by Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Leerink Partnrs raised their FY2026 earnings estimates for shares of Exelixis in a research note issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now expects that the biotechnology company will post earnings of $2.56 per share for the year, up from their previous forecast of $2.54. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share.

A number of other analysts have also recently commented on EXEL. Truist Financial boosted their price objective on Exelixis from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Monday, January 27th. JMP Securities restated a “market outperform” rating and set a $41.00 price objective on shares of Exelixis in a research report on Thursday, January 23rd. Stifel Nicolaus lifted their target price on shares of Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a research report on Wednesday, February 12th. Oppenheimer cut shares of Exelixis from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. Finally, Bank of America lowered shares of Exelixis from a “buy” rating to a “neutral” rating and raised their price target for the company from $35.00 to $39.00 in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Trading Down 0.4 %

NASDAQ EXEL opened at $36.70 on Monday. The stock has a market capitalization of $10.27 billion, a price-to-earnings ratio of 20.73, a PEG ratio of 1.13 and a beta of 0.57. The stock has a 50-day moving average of $35.71 and a 200 day moving average of $33.32. Exelixis has a twelve month low of $20.14 and a twelve month high of $40.02.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%.

Insiders Place Their Bets

In other news, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the transaction, the executive vice president now owns 303,310 shares in the company, valued at $11,216,403.80. The trade was a 14.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bob Oliver sold 18,647 shares of the company’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $37.25, for a total transaction of $694,600.75. Following the completion of the sale, the director now directly owns 33,514 shares of the company’s stock, valued at $1,248,396.50. This represents a 35.75 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 140,343 shares of company stock valued at $5,177,234. Insiders own 2.85% of the company’s stock.

Institutional Investors Weigh In On Exelixis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tri Ri Asset Management Corp acquired a new position in shares of Exelixis in the 3rd quarter valued at $4,396,000. Blue Trust Inc. lifted its position in Exelixis by 134.7% in the fourth quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 8,208 shares during the last quarter. Range Financial Group LLC purchased a new position in Exelixis during the fourth quarter worth about $994,000. FMR LLC increased its position in shares of Exelixis by 6.1% during the third quarter. FMR LLC now owns 2,462,072 shares of the biotechnology company’s stock valued at $63,891,000 after acquiring an additional 140,568 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Exelixis by 82.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after acquiring an additional 704,786 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.